Pogue; Sarah L.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Pogue; Sarah L..The latest application filed is for "combination of lenalidomide and polypeptide construct, and uses thereof".

Company Profile

3.16.17

Pogue; Sarah L. - North Wales PA
Pogue; Sarah L. - Fremont CA
Pogue; Sarah L. - Freemont CA
Pogue; Sarah L. - Frazer PA
Pogue; Sarah L. - Milpitas CA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Combination of lenalidomide and polypeptide construct, and uses thereof Grant 11,253,591 - Pogue , et al. February 22, 2	2022-02-22
Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B Grant 11,117,975 - Clarke , et al. September 14, 2	2021-09-14
Fusions of antibodies to CD38 and attenuated interferon alpha Grant 10,981,986 - Wilson, Jr. , et al. April 20, 2	2021-04-20
Combination Of Lenalidomide And Polypeptide Construct, And Uses Thereof App 20190151447 - Pogue; Sarah L. ; et al.	2019-05-23
Combination of lenalidomide and polypeptide construct, and uses thereof Grant 10,232,041 - Pogue , et al.	2019-03-19
Anti-cd38 Antibodies And Fusions To Attenuated Interferon Alpha-2b App 20180305460 - Clarke; Adam ; et al.	2018-10-25
Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B Grant 9,963,515 - Clarke , et al. May 8, 2	2018-05-08
Fusions Of Antibodies To Cd38 And Attenuated Interferon Alpha App 20170233449 - Wilson, Jr.; David S. ; et al.	2017-08-17
Combination Of Lenalidomide And Polypeptide Construct, And Uses Thereof App 20170202962 - Pogue; Sarah L. ; et al.	2017-07-20
Combination of lenalidomide and polypeptide construct, and uses thereof Grant 9,636,334 - Pogue , et al. May 2, 2	2017-05-02
Fusions of antibodies to CD38 and attenuated interferon alpha Grant 9,611,322 - Wilson, Jr. , et al. April 4, 2	2017-04-04
Polypeptide Constructs And Uses Thereof App 20160367695 - Wilson; David S. ; et al.	2016-12-22
Anti-cd38 Antibodies And Fusions To Attenuated Interferon Alpha-2b App 20160068612 - Clarke; Adam ; et al.	2016-03-10
Combination of Lenalidomide and Polypeptide Construct, and Uses Thereof App 20150313965 - Pogue; Sarah L. ; et al.	2015-11-05
Polypeptide Constructs And Uses Thereof App 20140248238 - Wilson, JR.; David S. ; et al.	2014-09-04
Monoclonal antibodies against stromal derived factor-1 (SDF-1) Grant 8,496,931 - Pogue , et al. July 30, 2	2013-07-30
Human Antibodies That Bind Mesothelin, And Uses Thereof App 20130190481 - TERRETT; JONATHAN A. ; et al.	2013-07-25
Human antibodies that bind mesothelin, and uses thereof Grant 8,425,904 - Terrett , et al. April 23, 2	2013-04-23
Human antibodies that bind mesothelin, and uses thereof Grant 8,399,623 - Terrett , et al. March 19, 2	2013-03-19
Human antibodies that bind mesothelin, and uses thereof Grant 8,383,779 - Terrett , et al. February 26, 2	2013-02-26
Human Antibodies That Bind Mesothelin, And Uses Thereof App 20130028906 - Terrett; Jonathan A. ; et al.	2013-01-31
Human Antibodies That Bind Mesothelin, And Uses Thereof App 20130028905 - Terrett; Jonathan A. ; et al.	2013-01-31
Human Antibodies That Bind Mesothelin, And Uses Thereof App 20130028904 - Terrett; Jonathan A. ; et al.	2013-01-31
Human antibodies that bind mesothelin, and uses thereof Grant 8,268,970 - Terrett , et al. September 18, 2	2012-09-18
Human Antibodies That Bind Mesothelin, And Uses Thereof App 20110262448 - TERRETT; Jonathan A. ; et al.	2011-10-27
Monoclonal Antibodies Against Stromal Derived Factor-1 (sdf-1) App 20100158902 - Pogue; Sarah L. ; et al.	2010-06-24

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.